论文部分内容阅读
目的:应用导管介入性治疗小儿多种先天性心脏病并对其疗效进行初步评价,为小儿多种先天性心脏病的治疗提供科学的指导依据。方法:选取我院在2013年1月到2015年7月收治的280例小儿多种先天性心脏病作为本研究的研究对象,并对这些研究对象的临床资料进行回顾性分析,患者中男138例,女142例,年龄范围在5个月到14岁,平均年龄3.3±2.5岁,134例动脉导管未闭(PDA),96例继发孔中央型房间隔缺损(ASD),42例室间隔缺损(VSD)8例,肺动脉瓣膜狭窄(PS).280均采用国产的封堵器及球囊行先天性心脏病介入封堵术及球囊肺动脉瓣成型术。结果:观察患者的治疗效果,全组手术成功率为100%。术后第1、3、6、12月随访,随访时间1年(共4次),无分流、导管再通及堵闭器移位,治疗效果满意。结论:对于小儿多种先天性心脏病患者,为患者采用导管介入治疗小儿先天性心脏病是有效的微创手术治疗方法,治疗效果好,手术创伤小,术后恢复快,无疤痕形成。可以有效地提高患者治疗的有效率,促进其生理及心理健康生活,值得在小儿多种先天性心脏病的治疗中推广使用。
Objective: To evaluate the curative effect of multiple congenital heart disease in children with interventional catheterization and to provide a scientific basis for the treatment of many congenital heart diseases in children. Methods: A total of 280 children with congenital heart disease admitted to our hospital from January 2013 to July 2015 were selected as the study subjects. The clinical data of these subjects were retrospectively analyzed. Among them, male 138 Cases, female 142 cases, the age range of 5 months to 14 years, mean age 3.3 ± 2.5 years, 134 cases of patent ductus arteriosus (PDA), 96 cases of secondary central atrial septal defect (ASD), 42 cases of room 8 cases of VSD, and PS of PS.280 were all treated with domestic occluder and balloon occlusion of congenital heart disease and balloon pulmonary valvuloplasty. Results: The therapeutic effect of the patients was observed. The success rate of the whole operation was 100%. The patients were followed up for 1, 3, 6 and 12 months after operation, and the follow-up time was 1 year (total 4 times). No shunt, catheter recanalization and occluder displacement were achieved. The therapeutic effect was satisfactory. Conclusion: For children with multiple congenital heart disease, catheterization for pediatric patients with congenital heart disease is an effective minimally invasive surgical treatment, the effect is good, less trauma, postoperative recovery, no scar formation. Can effectively improve the efficiency of patient treatment and promote their physical and mental health of life, it is worth in children with a variety of congenital heart disease treatment to promote the use.